EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction

Rashed Al-Marmouri

Global Cardiology Science and Practice · 22.05.2026 · 2026 (S2)

DOI: 10.21542/gcsp.2026.s2.78 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 22.05.2026. Verfasst von Rashed Al-Marmouri. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), is a foundational therapy for heart failure with reduced ejection fraction (HFrEF), proven in randomized trials to reduce mortality and hospitalizations. However, translating these results into real-world clinical practice requires evaluation in broader, less selected patient populations. This study assessed the real-world effectiveness and safety of sacubitril/valsartan in patients with HFrEF, focusing on mortality, rehospitalization, functional improvement, and tolerability.

Methods

We conducted a retrospective cohort analysis of approximately 5,400 patients with HFrEF initiated on sacubitril/valsartan between 2016 and 2023. Data were collected from linked electronic health records and national registries, including baseline demographics, NYHA functional class, and laboratory parameters. The primary endpoints were all-cause mortality and heart failure–related hospitalizations, while secondary outcomes included changes in NYHA class and treatment-emergent adverse events such as renal dysfunction, hyperkalemia, and hypotension. Each patient’s outcomes after ARNI initiation were compared with their pre-treatment period, with subgroup analyses performed in older adults (≥75 years) and those with advanced functional limitation (NYHA III/IV).

Results

Over a mean follow-up of more than five years, initiation of sacubitril/valsartan was associated with significant clinical improvement. NYHA functional class improved markedly from baseline (p

Zitieren

APA

Al-Marmouri, R. (2026). Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction. Global Cardiology Science and Practice, 2026(S2). https://doi.org/10.21542/gcsp.2026.s2.78

Vancouver

Al-Marmouri R. Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction. Global Cardiology Science and Practice. 2026;2026(S2). doi:10.21542/gcsp.2026.s2.78

BibTeX
@article{AlMarmouri2026,
  author = {Al-Marmouri, Rashed},
  title = {Real-World Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction},
  journal = {Global Cardiology Science and Practice},
  year = {2026},
  volume = {2026},
  number = {S2},
  doi = {10.21542/gcsp.2026.s2.78}
}
Kostenlos starten →